[go: up one dir, main page]

BR112022002579A2 - Anticorpos contra ilt2 e uso dos mesmos - Google Patents

Anticorpos contra ilt2 e uso dos mesmos

Info

Publication number
BR112022002579A2
BR112022002579A2 BR112022002579A BR112022002579A BR112022002579A2 BR 112022002579 A2 BR112022002579 A2 BR 112022002579A2 BR 112022002579 A BR112022002579 A BR 112022002579A BR 112022002579 A BR112022002579 A BR 112022002579A BR 112022002579 A2 BR112022002579 A2 BR 112022002579A2
Authority
BR
Brazil
Prior art keywords
ilt2
methods
antibodies against
antibodies
treating cancer
Prior art date
Application number
BR112022002579A
Other languages
English (en)
Inventor
Anna Fridman-Dror
Avidor Shulman
Haves Ziv Dana
Dror Alishekevitz
Ilana Goldshtein
Ilana Mandel
Motti Hakim
Tehila Ben-Moshe
Tsuri Peretz
Yair Sapir
Original Assignee
Biond Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biond Biologics Ltd filed Critical Biond Biologics Ltd
Publication of BR112022002579A2 publication Critical patent/BR112022002579A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

anticorpos contra ilt2 e uso dos mesmos. a presente invenção refere-se a anticorpos monoclonais, ou porções de ligação ao antígeno dos mesmos, contra ilt2, bem como composições farmacêuticas compreendendo os mesmos e métodos de produção dos mesmos. também são fornecidos métodos para tratar câncer compreendendo administrar os anticorpos ou as composições da invenção. métodos para tratar câncer, tratamentos de combinação e seleção de pacientes também são fornecidos.
BR112022002579A 2019-08-12 2020-08-12 Anticorpos contra ilt2 e uso dos mesmos BR112022002579A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962885374P 2019-08-12 2019-08-12
US202063034569P 2020-06-04 2020-06-04
PCT/IL2020/050889 WO2021028921A1 (en) 2019-08-12 2020-08-12 Antibodies against ilt2 and use thereof

Publications (1)

Publication Number Publication Date
BR112022002579A2 true BR112022002579A2 (pt) 2022-06-14

Family

ID=72474346

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002579A BR112022002579A2 (pt) 2019-08-12 2020-08-12 Anticorpos contra ilt2 e uso dos mesmos

Country Status (15)

Country Link
US (2) US11236162B2 (pt)
EP (1) EP4013510A1 (pt)
JP (2) JP7284256B2 (pt)
KR (2) KR102433076B1 (pt)
CN (1) CN114555637A (pt)
AR (1) AR123212A1 (pt)
AU (1) AU2020328931A1 (pt)
BR (1) BR112022002579A2 (pt)
CA (1) CA3150428A1 (pt)
CO (1) CO2022002573A2 (pt)
IL (1) IL290551A (pt)
MX (1) MX2022001841A (pt)
PH (1) PH12022550333A1 (pt)
WO (1) WO2021028921A1 (pt)
ZA (1) ZA202202363B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328931A1 (en) 2019-08-12 2022-03-24 Biond Biologics Ltd. Antibodies against ILT2 and use thereof
EP4169950A4 (en) * 2020-07-28 2024-03-20 Lg Chem, Ltd. ANTI-LILRB1 ANTIBODIES AND ITS USES
US20230235055A1 (en) * 2020-07-28 2023-07-27 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use
KR20230058074A (ko) 2020-08-12 2023-05-02 비온드 바이오로직스 엘티디 Ilt2에 대한 항체 및 이의 용도
IL305794A (en) * 2021-03-11 2023-11-01 Univ Health Network LILRB1 and LILRB2 binding molecules and their uses
US20250197491A1 (en) 2022-03-11 2025-06-19 Macomics Limited Compositions and methods for modulation of macrophage activity
CA3254977A1 (en) * 2022-03-29 2023-10-05 Coherus Biosciences Inc CANCER TREATMENT METHODS
TW202436350A (zh) * 2023-02-02 2024-09-16 大陸商來凱醫藥科技（上海）有限公司 抗ｌｉｌｒｂ１及／或抗ｌｉｌｒｂ２抗體及其等用途
WO2024207855A1 (zh) * 2023-04-04 2024-10-10 成都优洛生物科技有限公司 抗lilrb1抗体或其抗原结合片段、制备方法和用途
TW202513590A (zh) * 2023-06-20 2025-04-01 中國商科望（蘇州）生物醫藥科技有限公司 與ｌｉｌｒｂ１結合的抗體或抗原結合片段及其用途
WO2025015190A1 (en) 2023-07-11 2025-01-16 Biond Biologics Ltd. Treatment of cancer with anti-ilt2 antibodies

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
JP5642328B2 (ja) 2003-07-24 2014-12-17 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｎｋ細胞増強化合物を使用する治療抗体の有効性を増大させる方法および組成物
SI2532681T1 (sl) * 2005-12-20 2015-03-31 Sbi Biotech Co., Ltd. Protitelo proti-ILT7
AU2007319359A1 (en) 2006-11-14 2008-05-22 Genentech, Inc. Modulators of neuronal regeneration
EP3209769B1 (en) 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
RS61901B1 (sr) 2016-01-21 2021-06-30 Innate Pharma Neutralizacija inhibitornih puteva u limfocitima
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
TWI796329B (zh) * 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
CN111867614A (zh) 2018-01-18 2020-10-30 艾达奈特公司 抗lilrb抗体及其用途
KR20210027436A (ko) 2018-06-29 2021-03-10 베링거 인겔하임 인터내셔날 게엠베하 자가면역 질환을 치료하는데 사용하기 위한 항-cd40 항체
MA53381A (fr) 2018-07-24 2021-06-02 Amgen Inc Association d'inhibiteurs de la voie lilrb1/2 et d'inhibiteurs de la voie pd-1
CN113330033B (zh) 2018-12-26 2024-11-29 先天制药公司 白细胞免疫球蛋白样受体2中和性抗体
AU2020328931A1 (en) 2019-08-12 2022-03-24 Biond Biologics Ltd. Antibodies against ILT2 and use thereof
US20240294634A1 (en) 2019-10-14 2024-09-05 Innate Pharma Treatment of cancer with ilt-2 inhibitors
CN119241708A (zh) 2019-12-23 2025-01-03 株式会社Lg化学 抗lilrb1抗体及其用途
JP2023523628A (ja) 2020-05-01 2023-06-06 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Ｉｌｔ結合剤及びその使用方法
KR20230058074A (ko) 2020-08-12 2023-05-02 비온드 바이오로직스 엘티디 Ilt2에 대한 항체 및 이의 용도

Also Published As

Publication number Publication date
JP2023103385A (ja) 2023-07-26
KR20220116575A (ko) 2022-08-23
ZA202202363B (en) 2024-06-26
AR123212A1 (es) 2022-11-09
PH12022550333A1 (en) 2023-06-14
JP7284256B2 (ja) 2023-05-30
AU2020328931A1 (en) 2022-03-24
WO2021028921A9 (en) 2021-05-20
WO2021028921A1 (en) 2021-02-18
JP2022536815A (ja) 2022-08-19
KR102433076B1 (ko) 2022-08-19
US20210277112A1 (en) 2021-09-09
MX2022001841A (es) 2022-08-17
US11236162B2 (en) 2022-02-01
US12391755B2 (en) 2025-08-19
CA3150428A1 (en) 2021-02-18
EP4013510A1 (en) 2022-06-22
US20220153836A1 (en) 2022-05-19
KR20210096598A (ko) 2021-08-05
CO2022002573A2 (es) 2022-06-21
IL290551A (en) 2022-04-01
CN114555637A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
BR112022002579A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
BR112023002301A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
MX2019010848A (es) Composiciones y procedimientos para el tratamiento del cancer.
ECSP15005280A (es) Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos
BR112019022972A2 (pt) Fomulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e métodos de uso das mesmas
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
MX2018003594A (es) Anticuerpo anti-garp.
EA201490622A1 (ru) Агенты, связывающие фактор роста эндотелия сосудов (vegf)/дельта-подобный лиганд (dll4), и их применение
JOP20190187A1 (ar) مترافقات عقار جسم مضاد لـ ccr7
EA202092518A1 (ru) Композиции и способы лечения рака
SA523440622B1 (ar) أجسام مضادة
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
EA201990988A1 (ru) Антитела против chikv и пути их применения
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
BR112022026341A2 (pt) Anticorpos e métodos para o tratamento de doenças associadas à claudina
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
BR112018015090A2 (pt) anticorpo anti-trombina, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
BR112016023011A2 (pt) tratamento de câncer gástrico
BR112021021060A2 (pt) Anticorpos anti-cd38 e formulações
MX2022004058A (es) Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.